492 related articles for article (PubMed ID: 33462671)
1. The roles of signaling pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV.
Hemmat N; Asadzadeh Z; Ahangar NK; Alemohammad H; Najafzadeh B; Derakhshani A; Baghbanzadeh A; Baghi HB; Javadrashid D; Najafi S; Ar Gouilh M; Baradaran B
Arch Virol; 2021 Mar; 166(3):675-696. PubMed ID: 33462671
[TBL] [Abstract][Full Text] [Related]
2. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
3. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
[TBL] [Abstract][Full Text] [Related]
4. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
5. Gene signatures and potential therapeutic targets of Middle East respiratory syndrome coronavirus (MERS-CoV)-infected human lung adenocarcinoma epithelial cells.
Wu YH; Yeh IJ; Phan NN; Yen MC; Hung JH; Chiao CC; Chen CF; Sun Z; Hsu HP; Wang CY; Lai MD
J Microbiol Immunol Infect; 2021 Oct; 54(5):845-857. PubMed ID: 34176764
[TBL] [Abstract][Full Text] [Related]
6. Man-Specific Lectins from Plants, Fungi, Algae and Cyanobacteria, as Potential Blockers for SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) Coronaviruses: Biomedical Perspectives.
Barre A; Van Damme EJM; Simplicien M; Le Poder S; Klonjkowski B; Benoist H; Peyrade D; Rougé P
Cells; 2021 Jun; 10(7):. PubMed ID: 34203435
[TBL] [Abstract][Full Text] [Related]
7. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.
Qian Y; Lei T; Patel PS; Lee CH; Monaghan-Nichols P; Xin HB; Qiu J; Fu M
J Virol; 2021 Nov; 95(23):e0139621. PubMed ID: 34549987
[TBL] [Abstract][Full Text] [Related]
8. Valinomycin as a potential antiviral agent against coronaviruses: A review.
Zhang D; Ma Z; Chen H; Lu Y; Chen X
Biomed J; 2020 Oct; 43(5):414-423. PubMed ID: 33012699
[TBL] [Abstract][Full Text] [Related]
9. Human and novel coronavirus infections in children: a review.
Rajapakse N; Dixit D
Paediatr Int Child Health; 2021 Feb; 41(1):36-55. PubMed ID: 32584199
[TBL] [Abstract][Full Text] [Related]
10. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
12. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
Khare P; Sahu U; Pandey SC; Samant M
Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
[TBL] [Abstract][Full Text] [Related]
13. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
14. UBR5 Acts as an Antiviral Host Factor against MERS-CoV via Promoting Ubiquitination and Degradation of ORF4b.
Zhou Y; Zheng R; Liu D; Liu S; Disoma C; Li S; Liao Y; Chen Z; Du A; Dong Z; Zhang Y; Liu P; Razzaq A; Chen D; Chen X; Zhong X; Liu S; Tao S; Liu Y; Xu L; Deng X; Li J; Jiang T; Zhao J; Li S; Xia Z
J Virol; 2022 Sep; 96(17):e0074122. PubMed ID: 35980206
[TBL] [Abstract][Full Text] [Related]
15. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
Mishra J; Prasun C; Sahoo PK; Nair MS
Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses.
Peng Y; Liu Y; Hu Y; Chang F; Wu Q; Yang J; Chen J; Teng S; Zhang J; He R; Wei Y; Bostina M; Luo T; Liu W; Qu X; Li YP
Front Immunol; 2022; 13():1056272. PubMed ID: 36618428
[TBL] [Abstract][Full Text] [Related]
18. Role of Toll-like receptors in the pathogenesis of COVID-19.
Khanmohammadi S; Rezaei N
J Med Virol; 2021 May; 93(5):2735-2739. PubMed ID: 33506952
[TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
20. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
